https://www.live-feeds.com/feed/novo-s-blockbuster-hopes-for-ckd-program-dwindle-after-more-phase-3-trials-scrappedContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novo-s-blockbuster-hopes-for-ckd-program-dwindle-after-more-phase-3-trials-scrappedhttps://www.live-feeds.com/feed/novo-s-blockbuster-hopes-for-ckd-program-dwindle-after-more-phase-3-trials-scrapped#u62272Wed, 09 Sep 2026 04:07:06 +0000Novo Nordisk has canceled two phase 3 cardiovascular trials for ziltivekimab, a drug designed to reduce inflammation and treat heart failure. These cancellations limit the company's ability to expand its growth beyond obesity treatments. Conversely, Novo Nordisk reports that semaglutide, marketed as Wegovy, successfully reduced obesity rates and helped children lose weight in recent clinical trials. The company now faces a split trajectory between failing heart disease programs and expanding pediatric applications for its weight loss portfolio.Why it mattersThe company has sought to diver